Nxera Pharma Management

Management criteria checks 2/4

Nxera Pharma's CEO is Chris Cargill, appointed in Mar 2022, has a tenure of 2.67 years. directly owns 0.046% of the company’s shares, worth ¥47.19M. The average tenure of the management team and the board of directors is 2.7 years and 5.7 years respectively.

Key information

Chris Cargill

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	2.7yrs
CEO ownership	0.05%
Management average tenure	2.7yrs
Board average tenure	5.7yrs

Recent management updates

Recent updates

Nxera Pharma Co., Ltd. (TSE:4565) Stocks Pounded By 25% But Not Lagging Industry On Growth Or Pricing

Sep 25

Nxera Pharma Co., Ltd.'s (TSE:4565) P/S Still Appears To Be Reasonable

Jun 26

Is Nxera Pharma (TSE:4565) A Risky Investment?

Apr 06

Sosei Group Corporation (TSE:4565) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable

Mar 08

CEO Compensation Analysis

How has Chris Cargill's remuneration changed compared to Nxera Pharma's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-JP¥4b
Jun 30 2024	n/a	n/a	-JP¥10b
Mar 31 2024	n/a	n/a	-JP¥9b
Dec 31 2023	n/a	n/a	-JP¥7b
Sep 30 2023	n/a	n/a	-JP¥3b
Jun 30 2023	n/a	n/a	JP¥2b
Mar 31 2023	n/a	n/a	JP¥1b
Dec 31 2022	JP¥292m	JP¥88m	JP¥382m
Sep 30 2022	n/a	n/a	-JP¥383m
Jun 30 2022	n/a	n/a	-JP¥224m
Mar 31 2022	n/a	n/a	JP¥100m
Dec 31 2021	JP¥231m	JP¥65m	JP¥1b
Sep 30 2021	n/a	n/a	JP¥1b
Jun 30 2021	n/a	n/a	JP¥1b
Mar 31 2021	n/a	n/a	JP¥1b
Dec 31 2020	JP¥157m	JP¥53m	JP¥1b
Sep 30 2020	n/a	n/a	-JP¥2b
Jun 30 2020	n/a	n/a	-JP¥1b
Mar 31 2020	n/a	n/a	-JP¥332m
Dec 31 2019	JP¥101m	JP¥40m	JP¥1b

Compensation vs Market: Insufficient data to establish whether Chris's total compensation is reasonable compared to companies of similar size in the JP market.

Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.

CEO

Chris Cargill (40 yo)

2.7yrs

Tenure

JP¥292,000,000

Compensation

Mr. Christopher Cargill, also known as Chris, serves as Representative Executive Officer, President, Chief Executive Officer and Director at Nxera Pharma Co., Ltd. (formerly known as Sosei Group Corporatio...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Shinichi Tamura	Founder & Chairman of the Board	19.4yrs	JP¥332.00m	0.66% ¥ 672.7m
Christopher Cargill	Representative Executive Officer	2.7yrs	JP¥292.00m	0.046% ¥ 47.2m
Hironoshin Nomura	Executive Officer	2.7yrs	no data	0.0016% ¥ 1.6m
Toshihiro Maeda	Executive VP & COO	less than a year	no data	no data
Kieran Johnson	Executive Officer	2.7yrs	no data	0.0077% ¥ 7.8m
Kazuhiko Yoshizumi	Executive Officer	6.8yrs	no data	0.0093% ¥ 9.4m
Shinichiro Nishishita	VP of Investor Relations & Head of Regulatory Disclosures	no data	no data	no data
Stacey Southall	Associate Director & Head of Biophysics	no data	no data	no data
Candelle Chong	Executive Officer	1.7yrs	no data	0.0063% ¥ 6.4m
Patrick Branch	Head of Business Development for Japan and the APAC region	less than a year	no data	no data
Makoto Sugita	President of Nxera Pharma Japan & Exe Officer	less than a year	no data	no data
Matthew Barnes	Hd. of Drug Disc. & UK R&D	2.7yrs	no data	0.0031% ¥ 3.2m

2.7yrs

Average Tenure

48yo

Average Age

Experienced Management: 4565's management team is considered experienced (2.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Shinichi Tamura	Founder & Chairman of the Board	19.4yrs	JP¥332.00m	0.66% ¥ 672.7m
Christopher Cargill	Representative Executive Officer	2.7yrs	JP¥292.00m	0.046% ¥ 47.2m
Malcolm Weir	Member of Scientific Advisory Board	1.2yrs	JP¥134.00m	no data
Rolf Kristian Berndtson Soderstrom	Independent External Director	4.7yrs	no data	0.016% ¥ 16.2m
Tomohiro Tohyama	Independent External Director	13.4yrs	no data	0.057% ¥ 58.0m
Noriaki Nagai	External Independent Director	5.7yrs	no data	0.038% ¥ 38.7m
Kuniaki Kaga	Independent External Director	6.4yrs	no data	0.040% ¥ 40.3m
David Roblin	Independent External Director	6.4yrs	no data	0.0073% ¥ 7.4m
Paul Leeson	Member of Scientific Advisory Board	no data	no data	no data
Peter Bernstein	Member of Scientific Advisory Board	no data	no data	no data
Richard Henderson	Member of Scientific Advisory Board	no data	no data	no data
Miwa Seki	External Independent Director	2.7yrs	no data	0.013% ¥ 12.8m

5.7yrs

Average Tenure

66yo

Average Age

Experienced Board: 4565's board of directors are considered experienced (5.7 years average tenure).

Nxera Pharma Management

Management criteria checks 2/4

Key information

Recent management updates

Nxera Pharma Co., Ltd. Appoints Makoto Sugita as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer of Nxera Pharma

Nxera Pharma Appoints Patrick Branch as Head of Business Development for Japan and APAC

Sosei Group Corporation, Annual General Meeting, Mar 27, 2024

Sosei Group Corporation Appoints Toshihiro Maeda as Chief Operating Officer

Sosei Group Corporation, Annual General Meeting, Mar 23, 2023

Sosei Group Corporation, Annual General Meeting, Mar 24, 2022

Recent updates

New minor risk - Share price stability

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Nxera Pharma Co., Ltd. Appoints Makoto Sugita as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer of Nxera Pharma

Nxera Pharma Co., Ltd. (TSE:4565) Stocks Pounded By 25% But Not Lagging Industry On Growth Or Pricing

Nxera Pharma Co., Ltd. to Report Q3, 2024 Results on Nov 01, 2024

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Nxera Pharma Co., Ltd.'s (TSE:4565) P/S Still Appears To Be Reasonable

Nxera Pharma Co., Ltd. to Report Q2, 2024 Results on Aug 09, 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568

Is Nxera Pharma (TSE:4565) A Risky Investment?

Nxera Pharma Appoints Patrick Branch as Head of Business Development for Japan and APAC

Sosei Group Corporation Doses First Subject in a Phase 1 Trial Evaluating its Novel EP4 Receptor Agonist, HTL0033744 (HTL'744) for the Treatment of Inflammatory Bowel Disease

Sosei Group Corporation (TSE:4565) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable

Sosei Group Corporation to Report Q1, 2024 Results on May 09, 2024

Now 24% undervalued after recent price drop

Full year 2023 earnings: EPS and revenues miss analyst expectations

Sosei Group Corporation, Annual General Meeting, Mar 27, 2024

Now 21% overvalued after recent price rise

Sosei Group Corporation Appoints Toshihiro Maeda as Chief Operating Officer

New minor risk - Shareholder dilution

Sosei Group Corporation Announces Marketing Approval for PIVLAZ (Clazosentan Sodium) 150 Mg in South Korea

Sosei Group Corporation to Report Fiscal Year 2023 Results on Feb 13, 2024

New minor risk - Share price stability

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Idorsia Pharmaceuticals Japan Ltd. Submits New Drug Application to the Japanese Pharmaceuticals and Medical Devices Agency for the Approval of Daridorexant

Price target decreased by 9.0% to JP¥2,281

Consensus revenue estimates increase by 12%

Sosei Group Corporation to Report Q3, 2023 Results on Nov 10, 2023

Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732

Second quarter 2023 earnings released: JP¥8.01 loss per share (vs JP¥17.95 loss in 2Q 2022)

Price target increased by 8.2% to JP¥2,443

Sosei Group Corporation (TSE:4565) entered into an agreement to acquire Idorsia Pharmaceuticals Japan Ltd/Idorsia Pharmaceuticals Korea Co., Ltd from Idorsia Ltd (SWX:IDIA) for JPY 65 billion.

Sosei Heptares Doses First Subject in Phase I Trial with HTL0048149, a First-in-Class GPR52 Agonist for Schizophrenia

Now 38% undervalued after recent price drop

Consensus EPS estimates fall by 30%

New major risk - Share price stability

Price target decreased by 16% to JP¥2,957

Sosei Group Corporation to Report Q2, 2023 Results on Aug 04, 2023

Price target increased by 8.9% to JP¥3,500

Now 21% undervalued

Consensus EPS estimates increase by 30%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 39%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Sosei Group Corporation, Annual General Meeting, Mar 23, 2023

Sosei Group Corporation to Report Fiscal Year 2022 Results on Feb 14, 2023

Third quarter 2022 earnings released: EPS: JP¥3.82 (vs JP¥5.80 in 3Q 2021)

Third quarter 2022 earnings released: EPS: JP¥3.82 (vs JP¥5.80 in 3Q 2021)

Sosei Group Corporation to Report Q3, 2022 Results on Nov 11, 2022

Price target increased to JP¥2,950

Second quarter 2022 earnings released: JP¥17.95 loss per share (vs JP¥14.11 loss in 2Q 2021)

Sosei Heptares' Oral, Selective M4 Receptor Agonist Advancing into Phase 2 Clinical Development Under Multi-Program Collaboration with Neurocrine Biosciences

Consensus revenue estimates increase by 18%

Cancer Research UK and Sosei Heptares Signs Agreement to Advance Cancer Immunotherapy Candidate into Clinical Trials

Sosei Group Corporation to Report Q2, 2022 Results on Aug 10, 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 15%

Price target decreased to JP¥2,600

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Sosei Group Corporation, Annual General Meeting, Mar 24, 2022

Sosei Heptares Receives Grant Funding from Wellcome to Advance the Development of Potent, Differentiated Oral Anti-Viral Small Molecules to Treat COVID-19

Consensus revenue estimates increase to JP¥16.5b

Price target increased to JP¥2,767

Third quarter 2021 earnings released: EPS JP¥5.80 (vs JP¥5.94 in 3Q 2020)

Consensus forecasts updated

Second quarter 2021 earnings released: JP¥14.11 loss per share (vs JP¥17.76 loss in 2Q 2020)